RT Book, Section
A1 Shalabi, Reem Abozena
A1 Frame, James N.
A2 Boyiadzis, Michael M.
A2 Frame, James N.
A2 Kohler, David R.
A2 Fojo, Tito
SR Print(0)
ID 1128367588
T1 Indications for Bone-Modifying Agents in Hematology-Oncology
T2 Hematology-Oncology Therapy, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071637893
LK hemonc.mhmedical.com/content.aspx?aid=1128367588
RD 2024/04/24
AB Primary  Indications  in  Patients  with  CancerTo  protect  bone  from  new  metastatic  lesionsTo  treat  hypercalcemia  of  malignancyTo  prevent  treatment-related  bone  demineralization,  osteolysis,  and  pathologic  fracturesTo  treat  osteolytic  lesions,  decrease  the  incidence  of  pathologic  fractures,  prevent  skeletal  deformities,  and  prevent  and  decrease  the  severity  of  pain